Genmab AS
GMAB: XCSE (DNK)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
DKK 4,399.00 | Pvkvzt | Yrrspzkf |
Genmab Benefits From Strong U.S. Dollar; Increasing FVE to DKK 2,490; Shares Fairly Valued
Narrow-Moat Genmab is benefiting from the strong U.S. dollar, which is contributing to higher revenue and overall higher operating profit. Management raised its USD/DKK exchange rate guidance to 6.8 for the year versus previous guidance of 6.4. We’ve updated our forecasts to account for the revised foreign-exchange guidance, and we’ve raised our fair value estimate to DKK 2,490. We view shares as fairly valued, and Genmab is currently trading in 3-star territory. We maintain our narrow moat rating, stable trend, and Medium Uncertainty Rating.